Jieshi Medical Completes Series B Financing Led by Yunsheng Investment to Accelerate Commercialization of Ophthalmic Implants
Investment Circle (ID: pedaily2012) June 24 News: Shanghai Jieshi Medical Technology Co., Ltd. ("Jieshi Medical") has successfully completedUniform Rise Investment Leads the Round，Xingliang Investment Follows the InvestmentTheSeries B Financing. The funds obtained will be used to accelerate the commercialization of core products, research and development of new products, and market expansion.
Shanghai Jieshi Medical Technology Co., Ltd. was established in January 2013 at the Zhangjiang Medical Device Industry Base. The company is dedicated to the research, development, and production of systematic solutions in the two major fields of fundus diseases and visual reconstruction. It has now preliminarily formed a product portfolio: Jieshi® Perfluoropropane Gas for Ophthalmic Use, Densiron® Perfluorooctane for Ophthalmic Surgery, a disposable ophthalmic puncture system, silicone oil injection and suction kits, eye irrigation (injection and suction) needles, and more products were the first to be approved for marketing in China. Silicone oil for ophthalmic surgery, disposable vitrectomy probes/laser fibers/illumination fibers, artificial corneal endothelium, and other products are currently in the research and development process.
Among them, the ophthalmic perfluoropropane gas (trade name: Jieshi®) independently developed by Shanghai Jieshi Medical Technology Co., Ltd. obtained the NMPA Class III certificate in February this year, becoming the first domestically produced disposable long-acting ophthalmic filling gas to be approved in China. The product is specifically designed for vitreoretinal surgery and used for intraocular filling treatment, effectively promoting the repositioning and healing of detached retinas.
Jieshi® Perfluoropropane Gas for Ophthalmology mainly consists of C3F8, which is colorless, transparent, and chemically stable, and can be used in the vitreous cavity. After injection, it is gradually excreted through the blood and respiratory system, eliminating the need for a second surgery to remove it. With its 30mL independent and binary protective packaging and disposable design, it directly addresses the pain points of high prices of imported products, repeated use, and the risk of hospital-acquired infections. Moreover, with a high purity of 99%, it redefines industry standards, completely ending the long-standing dilemma in China where domestically-produced long-acting gases were unavailable for retinal surgeries and patient treatments were delayed due to shortages of imported ophthalmic gases.
In addition, the perfluorooctane for ophthalmic surgery developed by Shanghai Jieshi Medical Technology Co., Ltd. (trade name: Heavy Water®) is also the only second-generation heavy water produced in China. Compared with the first-generation heavy water (mainly composed of perfluorodecalin, purity ≥ 95%), Jieshi Heavy Water® uses perfluorooctane as its main component. It has stable chemical properties, high inertness, and is unlikely to cause biological or enzymatic reactions in the body. It has higher purity (purity ≥ 99.98%); a smaller relative density, exerting less mechanical pressure on the retina under the same volume, making it safer; a larger relative vapor pressure (high vapor pressure at 35°C is 6.0-8.0 kPa), which makes it easy to volatilize post-surgery and less likely to leave residues; a refractive index (1.26) close to that of water (1.33), providing good color reproduction for the fundus, making it not only easier to identify but also maintaining good refractive media during surgery; a high boiling point (102-106°C), making it less prone to vaporization during intraocular photocoagulation.
For this round of financing,Founder of Jieshi Medical, Zhao HongbingExpress: Our heartfelt thanks to all investors for their trust and support in Jieshi Medical amidst the current environment! This high expectation bestows upon us a dual mission—to work diligently while aspiring for breakthroughs. The innovation and self-reliance of China's ophthalmic medical devices require the joint efforts of our industry peers. Let us join hands to draw up an independent blueprint and embark on a bright future together! The road ahead is long and fraught with challenges, but we shall reach our destination through persistent action; unwavering progress will eventually bring the dawn. For more brightness, we persevere!
Dr. Guo Yunlong, Founding Partner of Yunsheng InvestmentWith the trend of aging and economic development, the demand for diagnosis and treatment of ophthalmic diseases continues to increase. Shanghai Jieshi Medical Technology Co., Ltd. is a high-quality enterprise in China's ophthalmic medical device field. Through independent innovation and R&D, it has differentially laid out products in the two major fields of fundus diseases and visual reconstruction. Multiple self-developed products, such as perfluoropropane gas for ophthalmology and perfluorooctane heavy water for ophthalmology, have broken the gap in Chinese production. Additionally, several innovative products are expected to become the first products launched in China. The Jieshi Medical team has extensive R&D and operational experience in the ophthalmic device field, focusing on clinical pain points in product development, with the aim of benefiting a wide range of patients with ophthalmic diseases through independent innovation.
Yang Shixian, Managing Partner of Xingliang InvestmentEyes are the windows to the soul! In terms of the substitution rate for domestically produced ophthalmic medical devices, the field currently lags significantly behind other medical specialties in China. However, with the continuous emergence of innovative, forward-thinking, and diligent domestic ophthalmic device R&D and manufacturing enterprises like Shanghai Jieshi Medical Technology Co., Ltd., the future of ophthalmology in China is sure to be brighter! Shanghai Jieshi Medical Technology Co., Ltd. has initially formed a product matrix for vitreoretinal surgical consumables, with several products being the first to fill domestic gaps or debut on the market. It must leverage its advantages, excel in market sales, optimize professional services, and strengthen solutions—its prospects will undoubtedly be brilliant! Wishing Shanghai Jieshi Medical Technology Co., Ltd. continued success and further achievements!